FDA NEWS DIGEST -- JULY 1, 2002 FDA ISSUES STATEMENT ON ACRYLAMIDE IN FOODS -- Current information is "not sufficient" for FDA to determine the public health impact of acrylamide in foods, FDA Deputy Commissioner Lester M. Crawford, D.V.M., said in a statement. "FDA is unaware of any present data regarding acrylamide that would cause FDA to alter its current dietary recommendations for consumers." http://www.fda.gov/bbs/topics/NEWS/2002/NEW00817.html WARNINGS STRENGTHENED FOR BREAST CANCER DRUG NOLVADEX -- Serious, life-threatening or fatal events associated with Nolvadex (tamoxifen citrate) in a risk-reduction setting (for women at high risk for cancer and women with ductal carcinoma in situ) have prompted labeling changes for the drug. http://www.fda.gov/medwatch/SAFETY/2002/safety02.htm#nolvad NEW TEST GAUGES CHOLESTEROL IN SKIN -- FDA has cleared "Cholesterol 1, 2, 3," a new laboratory test that measures the amount of cholesterol in skin using the palm of the hand. The test is intended for people suspected of having severe coronary artery disease and those with a history of heart attack. http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01154.html ______________________________________________________ Thanks for subscribing to the FDA News Digest. Our next posting will be sent July 8. To leave this list at any time, send an e-mail to LISTSERV@LIST.NIH.GOV In the body of the message, write SIGNOFF FDA-NEWSDIGEST-L
